메뉴 건너뛰기




Volumn 16, Issue 8, 2011, Pages 1061-1068

KRAS and colorectal cancer: Ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice

Author keywords

Clinical trials; Colorectal neoplasms; Ethics; KRAS

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

EID: 80052210041     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0011     Document Type: Article
Times cited : (16)

References (24)
  • 1
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study
    • Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Díaz-Rubio, E.3
  • 2
    • 0027461840 scopus 로고
    • Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
    • Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
    • (1993) BMJ , vol.306 , pp. 752-755
    • Scheithauer, W.1    Rosen, H.2    Kornek, G.V.3
  • 3
    • 80052251529 scopus 로고    scopus 로고
    • Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century, Washington, DC: The National Academies Press
    • Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J, eds. Washington, DC: The National Academies Press, 2010:1-316.
    • (2010) Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J, Eds , pp. 1-316
  • 5
    • 84857106911 scopus 로고    scopus 로고
    • Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health. Transforming the NCI Clinical Trials Enterprise: Overview. Available at, accessed May 5
    • Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health. Transforming the NCI Clinical Trials Enterprise: Overview. Available at http://transformingtrials.cancer.gov/initiatives/overview, accessed May 5, 2011.
    • (2011)
  • 6
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lièvre A, Bachet JB, Le CorreDet al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66: 3992-3995.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3
  • 7
    • 40849118803 scopus 로고    scopus 로고
    • Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [abstract 7LB]
    • Amado RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [abstract 7LB]. Proc Eur Ca Conf 2007;5:8.
    • (2007) Proc Eur Ca Conf , vol.5 , pp. 8
    • Amado, R.G.1    Wolf, M.2    Freeman, D.3
  • 8
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 9
    • 42049092269 scopus 로고    scopus 로고
    • Interim results from PACCE: Irinotecan/ bevacizumab panitumumab as first-line treatment for metastatic colorectal cancer [abstract 279]
    • Hecht JR, Mitchell EP, Chidiac T et al. Interim results from PACCE: Irinotecan/ bevacizumab panitumumab as first-line treatment for metastatic colorectal cancer [abstract 279]. Proc GI Symp 2008;5:208.
    • (2008) Proc GI Symp , vol.5 , pp. 208
    • Hecht, J.R.1    Mitchell, E.P.2    Chidiac, T.3
  • 10
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]
    • Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]. Proc Am Soc Clin Oncol 2008;26:5s.
    • (2008) Proc Am Soc Clin Oncol , vol.5 s , pp. 26
    • van Cutsem, E.1    Lang, I.2    D'haens, G.3
  • 11
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience [abstract 4000]
    • Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience [abstract 4000]. Proc Am Soc Clin Oncol 2008;26:178s.
    • (2008) Proc Am Soc Clin Oncol , vol.178 s , pp. 26
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 12
    • 34447264101 scopus 로고    scopus 로고
    • Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract 4000]
    • Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract 4000]. Proc Am Soc Clin Oncol 2007;25:164s.
    • (2007) Proc Am Soc Clin Oncol , vol.164 s , pp. 25
    • van Cutsem, E.1    Nowacki, M.2    Lang, I.3
  • 13
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • van Cutsem, E.1    Köhne, C.H.2    Hitre, E.3
  • 14
    • 36348990562 scopus 로고    scopus 로고
    • Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study [abstract 4035]
    • Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study [abstract 4035]. Proc Am Soc Clin Oncol 2007;25:172s.
    • (2007) Proc Am Soc Clin Oncol , vol.172 s , pp. 25
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 15
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
    • (2009) J Clin Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 16
    • 78049341541 scopus 로고    scopus 로고
    • Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    • De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304: 1812-1820.
    • (2010) JAMA , vol.304 , pp. 1812-1820
    • de Roock, W.1    Jonker, D.J.2    di Nicolantonio, F.3
  • 17
    • 20244377544 scopus 로고    scopus 로고
    • Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate- dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13
    • Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate- dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-2220.
    • (2005) J Clin Oncol , vol.23 , pp. 2191-2220
    • Peters, W.P.1    Rosner, G.L.2    Vredenburgh, J.J.3
  • 18
    • 57449095367 scopus 로고    scopus 로고
    • Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    • Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
    • (2008) J Clin Oncol , vol.26 , pp. 5705-5712
    • di Nicolantonio, F.1    Martini, M.2    Molinari, F.3
  • 19
    • 80052229590 scopus 로고    scopus 로고
    • Association of BRAF mutations and EGFR intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients [abstract 4058]
    • Ruzzo A, Cremolini C, Loupakis F et al. Association of BRAF mutations and EGFR intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients [abstract 4058]. Proc Am Soc Clin Oncol 2009;27:15s.
    • (2009) Proc Am Soc Clin Oncol , vol.15 s , pp. 27
    • Ruzzo, A.1    Cremolini, C.2    Loupakis, F.3
  • 20
    • 78649739337 scopus 로고    scopus 로고
    • Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract 3506]
    • Bokemeyer C, Kohne C, Rougier P et al. Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract 3506]. Proc Am Soc Clin Oncol 2010;28:15s.
    • (2010) Proc Am Soc Clin Oncol , vol.15 s , pp. 28
    • Bokemeyer, C.1    Kohne, C.2    Rougier, P.3
  • 21
    • 70350204423 scopus 로고    scopus 로고
    • Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [abstract LBA4509]
    • Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [abstract LBA4509]. Proc Am Soc Clin Oncol 2009; 27:18s.
    • (2009) Proc Am Soc Clin Oncol , vol.18 s , pp. 27
    • van Cutsem, E.1    Kang, Y.2    Chung, H.3
  • 22
    • 49149109102 scopus 로고    scopus 로고
    • Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract LBA4011]
    • Punt CJ, Tol J, Rodenburg J et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract LBA4011]. Proc Am Soc Clin Oncol 2008;26:1008s.
    • (2008) Proc Am Soc Clin Oncol , vol.1008 s , pp. 26
    • Punt, C.J.1    Tol, J.2    Rodenburg, J.3
  • 23
    • 80052196969 scopus 로고    scopus 로고
    • Presented in part at the World Congress on Gastrointestinal Cancer
    • Presented in part at the World Congress on Gastrointestinal Cancer, Barcelona, June 25-28, 2008.
    • (2008) Barcelona, June , pp. 25-28
  • 24
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765.
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.